Neuralink's Vertically Integrated Therapy

Vertical integration is the product in Neuralink’s case, because the company is not selling a chip by itself, it is selling a full treatment pathway that starts with the implant, runs through a custom surgical robot and patient software, and ends with a hospital delivering the procedure to a person with paralysis. That makes Neuralink look less like a component supplier and more like a new implanted therapy category, where hospital adoption, clinical workflow, and reimbursement matter as much as device performance.1 2 3 4

• The B2B2C structure is concrete. Neuralink’s first human study covers the N1 Implant, the R1 Robot, and the N1 User App together, which means the hospital or trial site is the operating customer, while the end user is the patient who uses the system to control external devices.2
• This is also how the competitive map splits. Synchron is trying to make implantation look more like a vascular stent procedure through a blood vessel, with no open brain surgery, while Precision is building a surface electrode system and has already won FDA 510(k) clearance for a temporary cortical array. Neuralink is competing on the whole stack, not just signal quality.5 6 7 8
• Owning the stack can support stronger economics if Neuralink becomes the default clinical pathway. The company has raised about $1.2B and reached an estimated $9.65B valuation by June 2, 2025, while smaller BCI peers like Synchron and Precision were at roughly $345M and $430M of total estimated funding, which shows investors are underwriting a much bigger systems company outcome.1

The next phase is a race to turn brain computer interfaces from bespoke trials into repeatable hospital procedures. The company that makes implantation easier for surgeons, smoother for rehab teams, and easier for payers to reimburse will have the advantage, because in this market the winning product is the clinical workflow, not just the electrode.3 4 5 6 7 8